# Epitalon: Research Overview — Supernova Peptides > A literature summary of Epitalon (AEDG tetrapeptide), the lead Longevity & Cellular Health research peptide: telomerase mechanism, pineal-melatonin axis, rodent lifespan data, human observational evidence, and regulatory status. The synthetic AEDG tetrapeptide — studied for telomerase activation and pineal-melatonin regulation in aging — with a data record that is promising in scope but narrow in independent replication. ## The short version **Epitalon** is a synthetic peptide just four amino acids long — alanine, glutamic acid, aspartic acid, glycine, abbreviated AEDG. It was developed from research on epithalamin, a polypeptide extract of the bovine pineal gland, by Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. The proposed mechanism has two parts: it may stimulate the pineal gland's production of melatonin [3], and it may activate telomerase, the enzyme that extends the protective caps (telomeres) on chromosomes [4][2]. Here is the honest picture. The core findings — that Epitalon turns on telomerase in human cells and was associated with reduced mortality in an elderly cohort — are real published results, but they originate almost entirely from one Russian research lineage and received limited independent replication until 2024-2025 [1]. A 2025 systematic review explicitly notes that physico-chemical and structural characterization of the peptide remains limited [1]. The human mortality data are observational, not randomized or placebo-controlled [5]. This page summarizes what was studied; it gives no dose, no protocol, and no medical advice. ## What it is Epitalon is the synthetic version of the active sequence identified in epithalamin, the natural polypeptide extract of bovine pineal gland tissue. Its four-residue sequence is Ala-Glu-Asp-Gly (AEDG), and its connectivity SMILES is CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)O)C(=O)NCC(=O)O)N. You will also see it spelled *Epithalon* or *Epithalone* — these are variant transliterations of the same compound from Russian-language sources. An important distinction runs through the whole literature: **Epithalamin** (the natural bovine pineal extract) and **Epitalon** (the synthetic tetrapeptide) are legally and chemically different substances. Much of the early human and animal evidence used epithalamin; Epitalon is the synthetic derivative hypothesized to carry the active sequence. Conflating their evidence bases is a common error in secondary sources and marketing material. ## How it works Two primary mechanisms are described in the literature, both derived largely from in vitro and animal experiments. **Telomerase axis.** The best-replicated cellular result is that Epitalon can activate telomerase — specifically the catalytic subunit hTERT — in human cells, extending telomere length [4][2]. In human fetal fibroblasts that were initially telomerase-negative, adding the peptide induced hTERT expression, telomerase enzymatic activity, and measurable telomere elongation [4]. A 2025 study in normal human fibroblasts and breast-cancer cell lines found dose-dependent telomere lengthening at 0.1-1 µg/mL; the mechanism differed by cell type — hTERT-dependent in normal cells, Alternative Lengthening of Telomeres (ALT) in cancer lines [2]. Telomerase reactivation is a double-edged phenomenon: it can extend replicative lifespan in normal cells but is also a hallmark of most cancers, and the long-term oncological implications in humans are unresolved. **Pineal-melatonin axis.** In rat pinealocyte culture, the AEDG peptide stimulated the rate-limiting melatonin-synthesis enzyme AANAT and its transcription factor pCREB, raising melatonin levels in the culture medium [3]. The framing is that age-related decline in pineal melatonin output — which disrupts circadian rhythm and neuroendocrine signaling — may be partly correctable via this peptide route. A hypothesized epigenetic component (binding to histone H1 subtypes and specific DNA motifs, associated with chromatin decondensation in aged cells) is described in the 2025 review but explicitly qualified as uncertain [1]. A 2025 review in *International Journal of Molecular Sci* characterizes these mechanisms while noting that it remains uncertain whether they are the only mechanisms of action, and that structural and physico-chemical investigation of the peptide remains quite limited [1]. ## What the research shows **Cellular telomerase work.** The foundational 2003 cell study showed that adding Epithalon to telomerase-negative human fetal fibroblasts induced hTERT expression and telomere elongation — cells that lacked telomerase activity gained it [4]. The 2025 replication in multiple human cell lines confirmed dose-dependent telomere lengthening through two distinct mechanisms (telomerase in normal cells, ALT in cancer lines) and is the strongest independent corroboration to date [2]. **Pinealocyte culture.** In Wistar rat pinealocyte cultures, Epitalon (as AEDG) increased AANAT enzyme activity and pCREB transcription factor synthesis, raising melatonin in the culture medium. Co-administration with norepinephrine potentiated these effects [3]. **Mouse lifespan study.** In female SHR mice, Epitalon at 1.0 µg/mouse subcutaneously (five days per month from three months of age) extended maximum lifespan by 12.3% and inhibited leukemia 6-fold without increasing total tumor incidence; chromosome aberrations in bone marrow were reduced 17.1% [6]. Mean lifespan was unchanged; the maximum-lifespan gain and leukemia inhibition are the reported findings. **Oocyte aging model.** Epitalon at 0.1 mM protected mouse oocytes against post-ovulatory aging in vitro, reducing reactive oxygen species and improving mitochondrial activity at 6, 12, and 24 hours — framed as a potential geroprotective effect on oocyte quality with aging [7]. **Observational human data.** In a 6-8 year observational study of 266 elderly persons, the pineal peptide Epithalamin — alone and combined with thymalin (a thymic peptide) — was associated with reduced mortality versus untreated controls [5]. Epithalamin alone was associated with a 1.6-1.8-fold mortality decrease; combined thymalin + Epithalamin given annually for six years was associated with a 4.1-fold decrease. This result has been widely cited but carries a critical caveat: the study was observational, lacking randomization and a placebo control arm by Western standards, so reported benefits cannot be separated from selection bias, expectation effects, or other confounders [5]. ## Reported effects, cautions & safety Community reports for Epitalon exist across longevity forums, though the compound's injectable research-chemical status means these are anecdotal, unverified, and deeply confounded. They are reported here as social signals, not evidence — *anecdotal, not clinical evidence*. Commonly reported positive signals include better or more restorative sleep, a sense of more stable circadian rhythm, increased daytime energy, and a general sense of well-being. A subset report mild cosmetic impressions (skin, hair). Several attribute these effects to the melatonin-axis mechanism, though no controlled human trial has documented any of these outcomes. **Equally important negative signals**: a very common outcome is no noticeable effect at all, which appears frequently enough in forum records to be a meaningful counterweight. Injection-site reactions (redness, soreness, bruising) are the most common physical complaint, consistent with any subcutaneous research-peptide injection. Transient drowsiness, vivid dreams, mild headache, and lightheadedness are occasionally mentioned. Experienced community members repeatedly flag that the product identity and purity of research-grade peptide vials are unverified, a concern independent of any drug effect. The formal cautions from the literature are more significant: - Epitalon has no FDA, EMA, or MHRA approval for any human indication and is classified as a research chemical [1]. - The evidence base is weighted heavily toward a single research lineage; independent replication remains limited, especially for the headline human claims [4][5]. - The only human efficacy data are from an observational cohort lacking randomization and a placebo arm [5]. - Telomerase activation carries an unresolved theoretical cancer concern; the 2025 study showed Epitalon increased telomere length in breast-cancer cell lines, an effect with unclear oncological implications [2]. - No pharmacokinetic study in humans has been published; the peptide's half-life in humans is inferred from short-peptide chemistry, not measured. - The anti-tumor signals from rodent carcinogenesis models used induced or transgenic cancer settings, not general oncological safety surveillance [6]. ## Where it fits in longevity research Among the three compounds on this desk, Epitalon is the lead and the one most specifically framed as a *geroprotector* — a compound studied to directly intervene in cellular aging processes at the telomere and neuroendocrine level. Its decades-long research arc, centered on one Russian institute, produced results that are genuinely interesting but that also carry a methodological asterisk at every stage: in vitro work done in one lab, animal lifespan data from a single SHR model, and human observations that are not randomized [1][5]. The 2024-2025 independent replication of the telomerase finding is the field's most meaningful update, moving Epitalon from a single-source story toward one with at least some external corroboration [2]. Read alongside [MOTS-c](/mots-c), which approaches aging through the mitochondrial metabolic axis, and [NAD+](/nad), which addresses the coenzyme substrate underlying sirtuin and DNA-repair signaling, Epitalon represents the cell-division and neuroendocrine side of the same aging-biology picture. See the [comparison page](/compare) for a direct side-by-side. ![Epitalon AEDG tetrapeptide and telomere-cap structure in cold indigo night palette](/images/epitalon.webp) --- An independent literature desk mapping the published science on geroprotective compounds — citations in evidence, judgment reserved.